Press Releases

Investor Relations

Filter by Year

July 5, 2019

Acer Therapeutics Announces Restructuring and Update on Pipeline Programs

Restructuring expected to extend cash runway through end of 2020 Acer plans to discuss EDSIVO™ CRL with FDA and will continue to advance additional pipeline products NEWTON, MA – July 5, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening […]

Read More
June 25, 2019

Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO™ (celiprolol) in vEDS Patients

NEWTON, MA – June 25, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its […]

Read More
May 31, 2019

Acer Therapeutics Announces Poster Presentation at Society for Vascular Medicine Annual Meeting

Pilot study using claims database suggests that a minority of U.S. vEDS patients (34%) are being treated with antihypertensive medications   Data show no significant difference in clinical event rates in vEDS patients taking antihypertensive medications compared to those not taking an antihypertensive medication   NEWTON, MA – May 31, 2019 – Acer Therapeutics Inc. […]

Read More
May 23, 2019

Acer Therapeutics to Present at Upcoming Investor Conferences

NEWTON, MA – May 23, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a corporate overview at upcoming investor conferences in June, including: the William […]

Read More
May 14, 2019

Acer Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

Acer executing on pre-commercial launch plan for EDSIVO™ while growing and advancing its pipeline   NEWTON, MA – May 14, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for […]

Read More
May 7, 2019

Acer Therapeutics to Present at UBS Global Healthcare Conference

NEWTON, MA – May 7, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a corporate overview at the UBS Global Healthcare Conference, May 20-22, 2019 […]

Read More
April 16, 2019

Acer Announces Publication of vEDS Patient Registry Data

Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data     NEWTON, MA – April 16, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical needs, today announced the publication of long-term […]

Read More
March 13, 2019

Acer Therapeutics to Participate in Upcoming Investor Conferences

  NEWTON, MA – March 13, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need, today announced that Acer’s management team will provide a corporate overview at upcoming investor conferences in March and April, […]

Read More
March 7, 2019

Acer Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

Acer Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update   Acer continues to progress toward goals of commercializing EDSIVO™ and advancing pipeline   NEWTON, MA – March 7, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious […]

Read More
January 2, 2019

Acer Therapeutics Announces In-license of Osanetant from Sanofi

Acer acquires worldwide rights to clinical-stage NK3 receptor antagonist     NEWTON, MA – January 2, 2019 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical need, today announced that it has entered into an exclusive […]

Read More
QUICK
NAV